Comparing blood-thinning treatments after ischemic stroke in people with cancer
Observes stroke recurrence and bleeding with antiplatelet or anticoagulant drugs in adults with cancer.
Plain-language title generated from the registry record
Registry title: A Prospective Study to Observe Clinical Outcomes in Patients Receiving Antiplatelet or Anticoagulant Therapy for Cancer-Associated Acute Ischemic Stroke
Key facts
- Where
- Beijing, ChinaSee the site
Where in China
- Xuanwu Hospital, Capital Medical UniversityBeijing, ChinaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Xuanwu Hospital, Beijing
- Trial code
- NCT07845903
- Record updated
- 29 September 2026
- Original description
The goal of this observational study is to learn about the effectiveness and safety of antiplatelet and anticoagulant treatments in people with a history of cancer who have acute ischemic stroke. The main questions it aims to answer are:Read full original descriptionShow less
A Prospective Observational Cohort Study Evaluating the Effectiveness and Safety of Antiplatelet and Anticoagulant Therapies in Patients With Active Cancer and Acute Ischemic Stroke
The goal of this observational study is to learn about the effectiveness and safety of antiplatelet and anticoagulant treatments in people with a history of cancer who have acute ischemic stroke. The main questions it aims to answer are:
* Are there differences in the risk of another stroke between people receiving antiplatelet treatment and those receiving anticoagulant treatment? * Are there differences in the risk of bleeding between the treatment groups? * Which clinical characteristics, imaging findings, cancer-related factors, and blood test results are associated with treatment outcomes?
Participants will:
* Receive antiplatelet treatment, anticoagulant treatment, or a combination of both, as selected by their treating physicians during routine clinical care. * Provide clinical information and blood samples for the study. * Complete follow-up assessments approximately 30, 90, 180, and 360 days after the stroke.
Researchers will compare recurrent stroke, bleeding, other blood clot-related events, functional recovery, and survival among participants receiving different antithrombotic treatments. The study will not assign or change participants' treatments.
Inclusion: Age 18 years or older; Diagnosis of acute ischemic stroke confirmed by clinical evaluation and brain imaging; Enrollment within 7 days after symptom onset or the time the participant was last known to be well; History of a malignant tumor, regardless of whether the cancer is currently active or inactive; Written informed consent provided by the participant or the participant's legally authorized representative.
Exclusion: Hematologic malignancy; Primary intracerebral hemorrhage, subarachnoid hemorrhage, or another non-ischemic type of stroke; Transient ischemic attack without evidence of acute ischemic stroke; Known severe congenital coagulation disorder; Pregnancy or breastfeeding; Collection of research blood samples would delay intravenous thrombolysis, mechanical thrombectomy, or other necessary treatment; Blood samples that do not meet the prespecified collection requirements or show severe hemolysis; Inability to obtain reliable medical history or outcome information from the participant, medical records, or an authorized representative.